Re: Kaba et al.: The effectiveness and safety of micropulse cyclophotocoagulation in the treatment of ocular hypertension and glaucoma (Ophthalmology Glaucoma. 2020;3:181-189) REPLY

被引：0
|
作者：
Yuen, Darana [1 ,2 ]
Kaba, Qayim [3 ]
Tam, Eric [1 ,2 ,4 ]
Somani, Sohel [1 ,2 ,4 ]
机构：
[1] Uptown Eye Specialists, Vaughan, ON, Canada
[2] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[3] Cardiff Univ, Sch Med, Cardiff, Wales
[4] William Osler Hlth Syst, Brampton, ON, Canada
来源：
OPHTHALMOLOGY GLAUCOMA | 2021年 / 4卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：E3 / E4
页数：2
相关论文
共 50 条
  • [31] Re: De Moraes et al.: 24-2 Visual fields miss central defects shown on 10-2 tests in glaucoma suspects, ocular hypertensives, and early glaucoma (Ophthalmology. 2017;124:1449-1456)
    Grassi, Piergiacomo
    Ho, Henrietta
    Lim, Kin Sheng
    OPHTHALMOLOGY, 2018, 125 (04) : E27 - E27
  • [32] Re: Li et al.: Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis (Ophthalmology 2016;123:129-40) REPLY
    Li, Tianjing
    Lindsley, Kristina
    Rouse, Benjamin
    Hong, Hwanhee
    Shi, Qiyuan
    Friedman, David S.
    Wormald, Richard
    Dickersin, Kay
    OPHTHALMOLOGY, 2016, 123 (11) : E66 - E66
  • [33] Re: Yu et al.: Risk of visual field progression in glaucoma patients with progressive retinal nerve fiber layer thinning (Ophthalmology. 2016;123:1201-1210) REPLY
    Leung, Christopher Kai-Shun
    Weinreb, Robert N.
    OPHTHALMOLOGY, 2017, 124 (04) : E40 - E40
  • [34] Re: Yoshikawa et al.: Increased nighttime blood pressure in patients with glaucoma: cross-sectional analysis of the LIGHT study (Ophthalmology. 2019;126:1366-1371) Reply
    Yoshikawa, Tadanobu
    Obayashi, Kenji
    Ogata, Nahoko
    OPHTHALMOLOGY, 2020, 127 (05) : E31 - E32
  • [35] Re: Nanji et al.: Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications (Ophthalmology 2014; 121: 994-1000) Reply
    Nanji, Afshan A.
    Galor, Anat
    Karp, Carol L.
    OPHTHALMOLOGY, 2014, 121 (12) : E66 - E67
  • [36] Re: Sabharwal et al.: Early endophthalmitis incidence and risk factors after glaucoma surgery in the Medicare population from 2016 to 2019(Ophthalmology. 2024;131:179-187) Reply
    Sabharwal, Jasdeep
    Dun, Chen
    Woreta, Fasika a.
    OPHTHALMOLOGY, 2024, 131 (09) : e38 - e38
  • [37] Re: Lee et al.: The association among blood pressure, blood pressure medications, and glaucoma in a nationwide electronic health records database (Ophthalmology. 2022;129:276-284.) REPLY
    Wang, Sophia y.
    Hu, Wendeng
    Singh, Kuldev
    OPHTHALMOLOGY, 2023, 130 (02) : E5 - E6
  • [38] Re: Gedde et al.: Treatment outcomes in the Primary Tube Versus Trabeculectomy (PTVT) study after 3 years of follow-up (Ophthalmology. 2020;127:333-345) REPLY
    Gedde, Steven J.
    Feuer, William J.
    Lim, Kin Sheng
    Barton, Keith
    Goyal, Saurabh
    Ahmed, Iqbal I. K.
    Brandt, James D.
    OPHTHALMOLOGY, 2020, 127 (07) : E45 - E46
  • [39] Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical PracticeEffectiveness and Safety of the Bimatoprost ImplantE. Mann et al.
    Eric Mann
    Jeffrey A. Kammer
    Gagan Sawhney
    Jella An
    Erica C. Werts
    Vanessa Vera
    Marcos Rivas
    Hongxin Lai
    Sadhana Sonparote
    E. Randy Craven
    Drugs, 2025, 85 (3) : 397 - 414
  • [40] Re: Muayad et al.: Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in type 2 diabetes (Ophthalmology. 2025;132:271-279 REPLY
    Shukla, Priya
    Shaia, Jacqueline k.
    Singh, Rishi p.
    Talcott, Katherine e.
    OPHTHALMOLOGY, 2025, 132 (03) : e42 - e43
12345